|
US6489458B2
(en)
|
1997-03-11 |
2002-12-03 |
Regents Of The University Of Minnesota |
DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
|
|
AU2003231048A1
(en)
|
2002-04-22 |
2003-11-03 |
Regents Of The University Of Minnesota |
Transposon system and methods of use
|
|
DK2160401T3
(da)
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusionsmolekyler og il-15-varianter
|
|
EP2160461B1
(en)
|
2007-07-04 |
2012-08-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Hyperactive variants of the transposase protein of the transposon system sleeping beauty
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
ES2528892T3
(es)
|
2012-07-30 |
2015-02-13 |
Nbe-Therapeutics Llc |
Identificación mediada por trasposición de proteínas de unión o funcionales específicas
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
AU2014268364A1
(en)
|
2013-05-24 |
2015-12-10 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
MX383150B
(es)
|
2014-06-02 |
2025-03-13 |
Us Health |
Receptores quiméricos de antígeno que tienen como diana a cd-19.
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
EP4400516A1
(en)
|
2014-12-15 |
2024-07-17 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
KR102615825B1
(ko)
|
2015-03-11 |
2023-12-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
전위효소 폴리펩타이드 및 이의 용도
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
US20190135894A1
(en)
|
2015-06-25 |
2019-05-09 |
iCell Gene Therapeuticics LLC |
COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
EP4342978A3
(en)
|
2016-09-01 |
2024-07-03 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
|
KR20190102259A
(ko)
*
|
2017-01-10 |
2019-09-03 |
인트렉손 코포레이션 |
신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
|
|
CN108728459B
(zh)
*
|
2017-04-24 |
2023-08-04 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
|
|
WO2018201794A1
(zh)
|
2017-05-02 |
2018-11-08 |
重庆精准生物技术有限公司 |
抗人cd19抗原的嵌合抗原受体及其应用
|
|
EP3635132A4
(en)
*
|
2017-06-07 |
2021-05-26 |
Intrexon Corporation |
EXPRESSION OF NOVEL CELL MARKERS
|
|
US11441132B2
(en)
|
2017-08-21 |
2022-09-13 |
European Molecular Biology Laboratory |
Mutated sleeping beauty transposase
|
|
KR20230052312A
(ko)
|
2017-09-15 |
2023-04-19 |
카이트 파마 인코포레이티드 |
관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
|
|
AU2018331517B2
(en)
|
2017-09-15 |
2024-10-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
PE20211266A1
(es)
|
2017-10-31 |
2021-07-19 |
Allogene Therapeutics Inc |
Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
|
|
CA3083779A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
WO2019159193A1
(en)
|
2018-02-13 |
2019-08-22 |
Indian Institute Of Technology Bombay |
Novel humanized anti-cd19 chimeric antigen receptor, its nucelic acid sequence and its preparation
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CN108383914A
(zh)
|
2018-02-23 |
2018-08-10 |
北京美康基免生物科技有限公司 |
一种基于cd19的嵌合抗原受体及其应用
|
|
EP3561053A1
(en)
*
|
2018-04-26 |
2019-10-30 |
Baylor College of Medicine |
Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019246546A1
(en)
|
2018-06-22 |
2019-12-26 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd37 and cd19
|
|
WO2020010235A1
(en)
|
2018-07-05 |
2020-01-09 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Car t cells that target b-cell antigens
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
KR102665280B1
(ko)
|
2018-10-31 |
2024-05-10 |
난트퀘스트, 인크. |
Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거
|
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
|
|
CN110951689A
(zh)
|
2018-11-30 |
2020-04-03 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
PL3886894T3
(pl)
|
2018-11-30 |
2024-07-01 |
Juno Therapeutics, Inc. |
Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej
|
|
CN109517799B
(zh)
|
2018-11-30 |
2022-07-26 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109468284A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109880802B
(zh)
|
2018-11-30 |
2022-12-13 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109468283A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
US12600760B2
(en)
|
2018-12-13 |
2026-04-14 |
The General Hospital Corporation |
Chimeric antigen receptors targeting CD79B and CD19
|
|
KR20210129125A
(ko)
|
2019-02-20 |
2021-10-27 |
시티 오브 호프 |
Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도
|
|
US20230348556A1
(en)
|
2019-02-21 |
2023-11-02 |
Arbele Limited |
Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP7664180B2
(ja)
|
2019-04-26 |
2025-04-17 |
アロジーン セラピューティクス，インコーポレイテッド |
リツキシマブ耐性キメラ抗原受容体およびその用途
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
US20200384027A1
(en)
|
2019-05-03 |
2020-12-10 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|